Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine

@article{Souglakos2008RibonucleotideRS,
  title={Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine},
  author={John Souglakos and Ioannis P. Boukovinas and M{\`i}quel Taron and Pilar Luaces M{\'e}ndez and Dimitrios Mavroudis and M Tripaki and Dora Hatzidaki and A Koutsopoulos and Eustathios Stathopoulos and Vassilis Georgoulias and Rafael Rosell},
  journal={British Journal of Cancer},
  year={2008},
  volume={98},
  pages={1710 - 1715}
}
Ribonucleotide reductase subunits M1 (RRM1) and M2 (RRM2) are involved in the metabolism of gemcitabine (2′,2′-difluorodeoxycytidine), which is used for the treatment of nonsmall cell lung cancer. The mRNA expression of RRM1 and RRM2 in tumours from lung adenocarcinoma patients treated with docetaxel/gemcitabine was assessed and the results correlated with clinical outcome. RMM1 and RMM2 mRNA levels were determined by quantitative real-time PCR in primary tumours of previously untreated… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 57 CITATIONS, ESTIMATED 46% COVERAGE

FILTER CITATIONS BY YEAR

2008
2019

CITATION STATISTICS

  • 2 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 23 REFERENCES

Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2004
VIEW 9 EXCERPTS
HIGHLY INFLUENTIAL

Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
VIEW 1 EXCERPT

Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
VIEW 1 EXCERPT